UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate

Journal of clinical pharmacology, 2020-05, Vol.60 (5), p.586-594

2020

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

Rinshō yakuri, 2017, Vol.48 (4), p.131-139

2017

Volltextzugriff (PDF)

Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023)

Journal of pharmaceutical sciences, 2015-01, Vol.104 (1), p.207-214

2015

Volltextzugriff (PDF)

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1

Drug metabolism and disposition, 2017-02, Vol.45 (2), p.137-144

2017

Volltextzugriff (PDF)

Disposition and Metabolism of Semagacestat, a γ-Secretase Inhibitor, in Humans

Drug metabolism and disposition, 2010-04, Vol.38 (4), p.554-565

2010

Volltextzugriff (PDF)

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole

Drug metabolism and disposition, 2012-10, Vol.40 (10), p.1945-1952

2012

Volltextzugriff (PDF)

Biological Changes in the Development and Neurodegeneration of Mild Cognitive Impairment and Alzheimer's Disease

Ayan-Oshodi, Mosun A

2013

Volltextzugriff (PDF)

Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans

Drug metabolism and disposition, 2010-04, Vol.38 (4), p.554

2010

Volltextzugriff (PDF)

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat

Journal of clinical pharmacology, 2020-01, Vol.60 (1), p.107-116

2020

Volltextzugriff (PDF)

TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY SUBJECTS OF SINGLE DOSES OF LY2599666, AN ANTIGEN BINDING FRAGMENT (FAB) OF A MONOCLONAL ANTIBODY THAT TARGETS SOLUBLE MONOMER Aβ LINKED TO A POLY(ETHYLENE GLYCOL) MOLECULE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P250-P250

2017

Volltextzugriff (PDF)

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Clinical pharmacology and therapeutics, 2003-03, Vol.73 (3), p.170-177

2003

Volltextzugriff (PDF)

Semagacestat Pharmacokinetics Are Not Significantly Affected by Formulation, Food, or Time of Dosing in Healthy Participants

Journal of clinical pharmacology, 2012-06, Vol.52 (6), p.904-913

2012

Volltextzugriff (PDF)

Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies

Journal of clinical psychopharmacology, 2012-06, Vol.32 (3), p.408-411

2012

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β

Journal of Alzheimer's disease, 2019-01, Vol.68 (1), p.137-144

2019

Volltextzugriff (PDF)

P1‐039: LANABECESTAT DOES NOT AFFECT PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_5), p.P282-P282

2018

Volltextzugriff (PDF)

LANABECESTAT DOES NOT AFFECT PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P282-P282

2018

Volltextzugriff (PDF)

Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia

International journal of clinical pharmacology and therapeutics, 2015-06, Vol.53 (6), p.462-470

2015

Volltextzugriff (PDF)

Effects of a novel [mGlu.sub.2/3] receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Psychopharmacology, 2012-02, Vol.219 (4), p.959

2012

Volltextzugriff (PDF)

Effects of a novel mGlu sub(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Psychopharmacology, 2012-02, Vol.219 (4), p.959-970

2012

Volltextzugriff (PDF)

Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Psychopharmacologia, 2012-02, Vol.219 (4), p.959-970

2012

Volltextzugriff (PDF)

Effects of a novel mGlu^sub 2/3^ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Psychopharmacology, 2012-02, Vol.219 (4), p.959

2012

Volltextzugriff (PDF)

Poster #220 A PHASE 1B STUDY INVESTIGATING THE POTENTIAL INTERACTION BETWEEN LY2140023 AND SECOND GENERATIONANTIPSYCHOTICS IN SUBJECTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER

Schizophrenia research, 2012-04, Vol.136, p.S169-S170

2012

Volltextzugriff (PDF)

QT effect of semagacestat at therapeutic and supratherapeutic doses

International journal of clinical pharmacology and therapeutics, 2012-04, Vol.50 (4), p.290-299

2012

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(22)
Dissertationen
(1)

Sprache

Englisch
(23)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(11)
Male
(11)
Pharmacology & Pharmacy
(11)
Adult
(10)
Middle Aged
(10)
Female
(8)
Young Adult
(8)
Aged
(6)
Amino Acids - Administration & Dosage
(5)
Amyloid Precursor Protein Secretases - Antagonists & Inhibitors
(5)
Cross-Over Studies
(5)
Administration, Oral
(4)
Alanine - Analogs & Derivatives
(4)
Alanine - Pharmacokinetics
(4)
Azepines - Pharmacokinetics
(4)
Biological And Medical Sciences
(4)
Drug Interactions
(4)
Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023)

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1

Disposition and Metabolism of Semagacestat, a γ-Secretase Inhibitor, in Humans

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole

Biological Changes in the Development and Neurodegeneration of Mild Cognitive Impairment and Alzheimer's Disease

Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat

TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY SUBJECTS OF SINGLE DOSES OF LY2599666, AN ANTIGEN BINDING FRAGMENT (FAB) OF A MONOCLONAL ANTIBODY THAT TARGETS SOLUBLE MONOMER Aβ LINKED TO A POLY(ETHYLENE GLYCOL) MOLECULE

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Semagacestat Pharmacokinetics Are Not Significantly Affected by Formulation, Food, or Time of Dosing in Healthy Participants

Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β

P1‐039: LANABECESTAT DOES NOT AFFECT PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN

LANABECESTAT DOES NOT AFFECT PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN

Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia

Effects of a novel [mGlu.sub.2/3] receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Effects of a novel mGlu sub(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Effects of a novel mGlu^sub 2/3^ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

Poster #220 A PHASE 1B STUDY INVESTIGATING THE POTENTIAL INTERACTION BETWEEN LY2140023 AND SECOND GENERATIONANTIPSYCHOTICS IN SUBJECTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER

QT effect of semagacestat at therapeutic and supratherapeutic doses

Suchergebnisse filtern